Furthermore, while the high complete pathological response rate is encouraging, the lack of clear predictive markers like Ki-67 means that the treatment's effectiveness cannot be confidently predicted based solely on tumor characteristics observed in our cohort. This evidence concerns the gene MKI67 and neoplasm.